Status:
COMPLETED
Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if combination therapy of weekly Taxotere™ with Iressa™ will increase the objective responses in measurable leasions in metastatic breast cancer
Eligibility Criteria
Inclusion
- Histologically confirmed mammary carcinoma
Exclusion
- prior taxane chemotherapy for metastatic disease or prior treatment with tyrosine kinase inhibitors inhibiting the EGF receptor.
- Prior hormone treatment or one type of anthracycline based treatment regimen without taxane for metastatic disease is allowed prior to inclusion.
- If the patient has been treated in the adjuvant or neoadjuvant setting with taxanes, inclusion is allowed when the first cycle of trial medication is started 12 months after the last course of adjuvant treatment
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00319618
Start Date
June 1 2003
End Date
June 1 2006
Last Update
December 18 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Oslo, Norway